Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

• Revenue in USD (TTM)0.00
• Net income in USD-264.16m
• Incorporated2017
• Employees196.00

• Location
  Scholar Rock Holding Corp301 BINNEY STREET, 3RD FLOORCAMBRIDGE 02142United StatesUSA
• Phone+1 (857) 259-3860
• Fax+1 (302) 655-5049
• Websitehttps://scholarrock.com/